BMP3; CTCF; NDRG4; SDC2; SEPT9; biomarkers; colorectal cancer; early detection; Oncology; Cancer Research
Abstract :
[en] In CRC, screening compliance is decreased due to the experienced discomfort associated with colonoscopy, although this method is the gold standard in terms of sensitivity and specificity. Promoter DNA methylation (hypomethylation or hypermethylation) has been linked to all CRC stages. Study objectives: to systematically review the current knowledge on approved biomarkers, reveal new potential ones, and inspect tactics that can improve performance. This research was conducted according to the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines; the risk of bias was evaluated using the revised Quality Assessment of Diagnostic Accuracy Studies criteria (QUADAS-2). The Web of Science® Core Collection, MEDLINE® and Scopus® databases were searched for original articles published in peer-reviewed journals with the specific keywords "colorectal cancer", "early detection", "early-stage colorectal cancer", "epigenetics", "biomarkers", "DNA methylation biomarkers", "stool or blood or tissue or biopsy", "NDRG4", "BMP3", "SEPT9", and "SDC2". Based on eligibility criteria, 74 articles were accepted for analysis. mSDC2 and mSEPT9 were frequently assessed in studies, alone or together as part of the ColoDefense panel test-the latter with the greatest performance. mBMP3 may not be an appropriate marker for detecting CRC. A panel of five methylated binding sites of the CTCF gene holds the promise for early-stage specific detection of CRC. CRC screening compliance and accuracy can be enhanced by employing a stool mt-DNA methylation test.
Disciplines :
Oncology
Author, co-author :
Anghel, Sorina-Andreea ✱; Université de Liège - ULiège > Département de pharmacie > Chimie pharmaceutique ; Department of Clinical Laboratory, Food Safety, "Carol Davila" University of Medicine and Pharmacy, 6 Traian Vuia Street, 020945 Bucharest, Romania ; Department of Molecular Cell Biology, Institute of Biochemistry, Splaiul Independentei 296, 060031 Bucharest, Romania
Ioniță-Mîndrican, Corina-Bianca ✱; Department of Clinical Laboratory, Food Safety, "Carol Davila" University of Medicine and Pharmacy, 6 Traian Vuia Street, 020945 Bucharest, Romania ; Department of Toxicology, Faculty of Pharmacy, "Carol Davila" University of Medicine and Pharmacy, 020945 Bucharest, Romania
Luca, Ioana; Department of Clinical Laboratory, Food Safety, "Carol Davila" University of Medicine and Pharmacy, 6 Traian Vuia Street, 020945 Bucharest, Romania
Pop, Anca Lucia ; Department of Clinical Laboratory, Food Safety, "Carol Davila" University of Medicine and Pharmacy, 6 Traian Vuia Street, 020945 Bucharest, Romania
✱ These authors have contributed equally to this work.
Language :
English
Title :
Promising Epigenetic Biomarkers for the Early Detection of Colorectal Cancer: A Systematic Review.
Siegel, R.L.; Miller, K.D.; Fuchs, H.E.; Jemal, A. Cancer Statistics, 2021. CA Cancer J. Clin. 2021, 71, 7–33. [CrossRef]
Kuipers, E.J.; Grady, W.M.; Lieberman, D.; Seufferlein, T.; Sung, J.J.; Boelens, P.G.; van de Velde, C.J.; Watanabe, T. Colorectal cancer. Nat. Rev. Dis. Primers 2015, 1, 15065. [CrossRef] [PubMed]
Rasool, S.; Kadla, S.A.; Rasool, V.; Ganai, B.A. A comparative overview of general risk factors associated with the incidence of colorectal cancer. Tumour Biol. 2013, 34, 2469–2476. [CrossRef] [PubMed]
Hong, S.N. Genetic and epigenetic alterations of colorectal cancer. Intest. Res. 2018, 16, 327–337. [CrossRef] [PubMed]
Okugawa, Y.; Grady, W.M.; Goel, A. Epigenetic Alterations in Colorectal Cancer: Emerging Biomarkers. Gastroenterology 2015, 149, 1204–1225.e12. [CrossRef]
Simon, K. Colorectal cancer development and advances in screening. Clin. Interv. Aging 2016, 11, 967–976. [CrossRef] [PubMed]
Allison, J.E.; Sakoda, L.C.; Levin, T.R.; Tucker, J.P.; Tekawa, I.S.; Cuff, T.; Pauly, M.P.; Shlager, L.; Palitz, A.M.; Zhao, W.K.; et al. Screening for colorectal neoplasms with new fecal occult blood tests: Update on performance characteristics. J. Natl. Cancer Inst. 2007, 99, 1462–1470. [CrossRef]
Symonds, E.L.; Pedersen, S.K.; Murray, D.; Byrne, S.E.; Roy, A.; Karapetis, C.; Hollington, P.; Rabbitt, P.; Jones, F.S.; LaPointe, L.; et al. Circulating epigenetic biomarkers for detection of recurrent colorectal cancer. Cancer 2020, 126, 1460–1469. [CrossRef]
Page, M.J.; McKenzie, J.E.; Bossuyt, P.M.; Boutron, I.; Hoffmann, T.C.; Mulrow, C.D.; Shamseer, L.; Tetzlaff, J.M.; Akl, E.A.; Brennan, S.E.; et al. The PRISMA 2020 statement: An updated guideline for reporting systematic reviews. BMJ 2021, 372, n71. [CrossRef]
Whiting, P.F.; Rutjes, A.W.; Westwood, M.E.; Mallett, S.; Deeks, J.J.; Reitsma, J.B.; Leeflang, M.M.; Sterne, J.A.; Bossuyt, P.M.; The QUADAS-2 Group. QUADAS-2: A revised tool for the quality assessment of diagnostic accuracy studies. Ann. Intern. Med. 2011, 155, 529–536. [CrossRef]
National Health Medical Research Council. NHMRC Additional Levels of Evidence and Grades for Recommendations for Developers of Guidelines; NHMRC: Canberra, Australia, 2009.
Hägg, S.; Jylhävä, J. Should we invest in biological age predictors to treat colorectal cancer in older adults? Eur. J. Surg. Oncol. 2020, 46, 316–320. [CrossRef]
Quan, Y.; Liang, F.; Wu, D.; Yao, X.; Hu, Z.; Zhu, Y.; Chen, Y.; Wu, A.; Tang, D.; Huang, B.; et al. Blood Cell DNA Methylation of Aging-Related Ubiquitination Gene DZIP3 Can Predict the Onset of Early Stage Colorectal Cancer. Front. Oncol. 2020, 10, 544330. [CrossRef]
Maugeri, A.; Barchitta, M.; Magnano San Lio, R.; Li Destri, G.; Agodi, A.; Basile, G. Epigenetic Aging and Colorectal Cancer: State of the Art and Perspectives for Future Research. Int. J. Mol. Sci. 2021, 22, 200. [CrossRef]
Zarkavelis, G.; Boussios, S.; Papadaki, A.; Katsanos, K.H.; Christodoulou, D.K.; Pentheroudakis, G. Current and future biomarkers in colorectal cancer. Ann. Gastroenterol. 2017, 30, 613–621. [CrossRef] [PubMed]
Tao, Y.; Kang, B.; Petkovich, D.A.; Bhandari, Y.R.; In, J.; Stein-O’Brien, G.; Kong, X.; Xie, W.; Zachos, N.; Maegawa, S.; et al. Aging-like Spontaneous Epigenetic Silencing Facilitates Wnt Activation, Stemness, and BrafV600E-Induced Tumorigenesis. Cancer Cell 2019, 35, 315–328.e6. [CrossRef] [PubMed]
Hannum, G.; Guinney, J.; Zhao, L.; Zhang, L.I.; Hughes, G.; Sadda, S.; Klotzle, B.; Bibikova, M.; Fan, J.-B.; Gao, Y.; et al. Genome-wide methylation profiles reveal quantitative views of human aging rates. Mol. Cell 2013, 49, 359–367. [CrossRef] [PubMed]
Horvath, S. DNA methylation age of human tissues and cell types. Genome Biol. 2013, 14, R115. [CrossRef]
Weidner, C.I.; Lin, Q.; Koch, C.M.; Eisele, L.; Beier, F.; Ziegler, P.; Bauerschlag, D.O.; Jöckel, K.H.; Erbel, R.; Mühleisen, T.W.; et al. Aging of blood can be tracked by DNA methylation changes at just three CpG sites. Genome Biol. 2014, 15, R24. [CrossRef] [PubMed]
Zheng, Y.; Joyce, B.T.; Colicino, E.; Liu, L.; Zhang, W.; Dai, Q.; Shrubsole, M.J.; Kibbe, W.A.; Gao, T.; Zhang, Z.; et al. Blood Epigenetic Age may Predict Cancer Incidence and Mortality. EBioMedicine 2016, 5, 68–73. [CrossRef]
Gào, X.; Zhang, Y.; Boakye, D.; Li, X.; Chang-Claude, J.; Hoffmeister, M.; Brenner, H. Whole blood DNA methylation aging markers predict colorectal cancer survival: A prospective cohort study. Clin. Epigenet. 2020, 12, 184. [CrossRef]
Dugué, P.-A.; Bassett, J.K.; Wong, E.M.; Joo, J.E.; Li, S.; Yu, C.; Schmidt, D.F.; Makalic, E.; Doo, N.W.; Buchanan, D.D.; et al. Biological Aging Measures Based on Blood DNA Methylation and Risk of Cancer: A Prospective Study. JNCI Cancer Spectr. 2021, 5, pkaa109. [CrossRef]
Wang, T.; Maden, S.K.; Luebeck, G.E.; Li, C.I.; Newcomb, P.A.; Ulrich, C.M.; Joo, J.H.E.; Buchanan, D.D.; Milne, R.L.; Southey, M.C.; et al. Dysfunctional epigenetic aging of the normal colon and colorectal cancer risk. Clin. Epigenet. 2020, 12, 3–11. [CrossRef]
Erichsen, L.; Beermann, A.; Arauzo-Bravo, M.J.; Hassan, M.; Dkhil, M.A.; Al-Quraishy, S.; Hafiz, T.A.; Fischer, J.C.; Santourlidis, S. Genome-wide hypomethylation of LINE-1 and Alu retroelements in cell-free DNA of blood is an epigenetic biomarker of human aging. Saudi J. Biol. Sci. 2018, 25, 1220–1226. [CrossRef]
Mahmood, W.; Erichsen, L.; Ott, P.; Schulz, W.A.; Fischer, J.C.; Arauzo-Bravo, M.J.; Bendhack, M.L.; Hassan, M.; Santourlidis, S. Aging-associated distinctive DNA methylation changes of LINE-1 retrotransposons in pure cell-free DNA from human blood. Sci. Rep. 2020, 10, 22127. [CrossRef] [PubMed]
Akimoto, N.; Zhao, M.; Ugai, T.; Zhong, R.; Lau, M.C.; Fujiyoshi, K.; Kishikawa, J.; Haruki, K.; Arima, K.; Twombly, T.S.; et al. Tumor Long Interspersed Nucleotide Element-1 (LINE-1) Hypomethylation in Relation to Age of Colorectal Cancer Diagnosis and Prognosis. Cancers 2021, 13, 2016. [CrossRef] [PubMed]
Duran-Sanchon, S.; Moreno, L.; Augé, J.M.; Serra-Burriel, M.; Cuatrecasas, M.; Moreira, L.; Castells, A. Identification and validation of microRNA profiles in fecal samples for detection of colorectal cancer. Gastroenterology 2020, 158, 947–957. [CrossRef]
Kim, J.H.; Park, S.C. Syndecan-2 Methylation as a New Biomarker for Early Detection of Colorectal Neoplasm. Gut Liver 2018, 12, 479–480. [CrossRef]
Lamb, Y.N.; Dhillon, S. Epi proColon®2.0 CE: A Blood-Based Screening Test for Colorectal Cancer. Mol. Diagn. Ther. 2017, 21, 225–232. [CrossRef] [PubMed]
Beltrán-García, J.; Osca-Verdegal, R.; Mena-Mollá, S.; García-Giménez, J.L. Epigenetic IVD Tests for Personalized Precision Medicine in Cancer. Front. Genet. 2019, 10, 621. [CrossRef]
Ferrari, A.; Neefs, I.; Hoeck, S.; Peeters, M.; Van Hal, G. Towards Novel Non-Invasive Colorectal Cancer Screening Methods: A Comprehensive Review. Cancers 2021, 13, 1820. [CrossRef] [PubMed]
Wang, Z.; Shang, J.; Zhang, G.; Kong, L.; Zhang, F.; Guo, Y.; Dou, Y.; Lin, J. Evaluating the clinical performance of a novel dual-target stool DNA test for colorectal cancer detection. medRxiv 2021. [CrossRef]
Niu, F.; Wen, J.; Fu, X.; Li, C.; Zhao, R.; Wu, S.; Yu, H.; Liu, X.; Zhao, X.; Liu, S.; et al. Stool DNA Test of Methylated Syndecan-2 for the Early Detection of Colorectal Neoplasia. Cancer Epidemiol. Prev. Biomark. 2017, 26, 1411–1419. [CrossRef] [PubMed]
Oh, T.J.; Oh, H.I.; Seo, Y.Y.; Jeong, D.; Kim, C.; Kang, H.W.; Han, Y.D.; Chung, H.C.; Kim, N.K.; An, S. Feasibility of quantifying SDC2 methylation in stool DNA for early detection of colorectal cancer. Clin. Epigenet. 2017, 9, 126. [CrossRef] [PubMed]
Park, Y.S.; Kim, D.S.; Cho, S.W.; Park, J.W.; Jeon, S.J.; Moon, T.J.; Kim, S.H.; Son, B.K.; Oh, T.J.; An, S.; et al. Analysis of Syndecan-2 Methylation in Bowel Lavage Fluid for the Detection of Colorectal Neoplasm. Gut Liver 2018, 12, 508–515. [CrossRef] [PubMed]
Han, Y.D.; Oh, T.J.; Chung, T.H.; Jang, H.W.; Kim, Y.N.; An, S.; Kim, N.K. Early detection of colorectal cancer based on presence of methylated syndecan-2 (SDC2) in stool DNA. Clin. Epigenet. 2019, 11, 51. [CrossRef]
Wang, J.; Liu, S.; Wang, H.; Zheng, L.; Zhou, C.; Li, G.; Huang, R.; Wang, H.; Li, C.; Fan, X.; et al. Robust performance of a novel stool DNA test of methylated SDC2 for colorectal cancer detection: A multicenter clinical study. Clin. Epigenet. 2020, 12, 162. [CrossRef]
Su, W.C.; Kao, W.Y.; Chang, T.K.; Tsai, H.L.; Huang, C.W.; Chen, Y.C.; Li, C.C.; Hsieh, Y.C.; Yeh, H.J.; Chang, C.C.; et al. Stool DNA test targeting methylated syndecan-2 (SDC2) as a noninvasive screening method for colorectal cancer. Biosci. Rep. 2021, 41, BSR20201930. [CrossRef]
Shayan, M.; Shariatpanahi, A.M.; Seifati, S.; Kerachian, M.A. Aberrant SEPT9 methylation in plasma cell-free DNA of CRC patients. Biomed. Res. 2018, 29, 3654–3659. [CrossRef]
Xie, L.; Jiang, X.; Li, Q.; Sun, Z.; Quan, W.; Duan, Y.; Li, D.; Chen, T. Diagnostic Value of Methylated Septin9 for Colorectal Cancer Detection. Front. Oncol. 2018, 8, 247. [CrossRef]
Yang, X.; Xu, Z.J.; Chen, X.; Zeng, S.S.; Qian, L.; Wei, J.; Peng, M.; Wang, X.; Liu, W.L.; Ma, H.Y.; et al. Clinical value of preoperative methylated septin 9 in Chinese colorectal cancer patients. World J. Gastroenterol. 2019, 25, 2099–2109. [CrossRef] [PubMed]
Sun, J.; Fei, F.; Zhang, M.; Li, Y.; Zhang, X.; Zhu, S.; Zhang, S. The role of mSEPT9 in screening, diagnosis, and recurrence monitoring of colorectal cancer. BMC Cancer 2019, 19, 450. [CrossRef] [PubMed]
Ma, Z.Y.; Law, W.L.; Ng, E.K.O.; Chan, C.S.Y.; Lau, K.S.; Cheng, Y.Y.; Shin, V.Y.; Kwong, A.; Leung, W.K. Methylated Septin 9 and Carcinoembryonic Antigen for Serological Diagnosis and Monitoring of Patients with Colorectal Cancer After Surgery. Sci. Rep. 2019, 9, 10326. [CrossRef] [PubMed]
.Liu, Y.; Zhao, G.; Miao, J.; Li, H.; Ma, Y.; Liu, X.; Li, S.; Zhu, Y.; Xiong, S.; Zheng, M.; et al. Performance Comparison Between Plasma and Stool Methylated SEPT9 Tests for Detecting Colorectal Cancer. Front. Genet. 2020, 11, 324. [CrossRef] [PubMed]
Houshmand, M.; Abbaszadegan, M.R.; Kerachian, M.A. Assessment of Bone Morphogenetic Protein 3 Methylation in Iranian Patients with Colorectal Cancer. Middle East J. Dig. Dis. 2017, 9, 158–163. [CrossRef] [PubMed]
Ashoori, H.; Ghamarchehreh, M.E.; Tavallaei, M.; Ganji, S.M.; Hosseini, M.; Zolfaghari, M.; Ghamarchehreh, Z.; Vahidian, F. Evaluation of the epigenetic biomarker bone morphogenic protein 3 for colorectal cancer diagnosis. J. Clin. Diagn. Res. 2018, 12, GC07–GC09. [CrossRef]
Chen, Y.; Wang, Z.; Zhao, G.; Sun, C.; Ma, Y.; Zhang, L.; Zheng, M.; Li, H. Performance of a Novel Blood-Based Early Colorectal Cancer Screening Assay in Remaining Serum after the Blood Biochemical Test. Dis. Markers 2019, 2019, 5232780. [CrossRef] [PubMed]
Zhao, G.; Li, H.; Yang, Z.; Wang, Z.; Xu, M.; Xiong, S.; Li, S.; Wu, X.; Liu, X.; Wang, Z.; et al. Multiplex methylated DNA testing in plasma with high sensitivity and specificity for colorectal cancer screening. Cancer Med. 2019, 8, 5619–5628. [CrossRef] [PubMed]
Zhao, G.; Liu, X.; Liu, Y.; Li, H.; Ma, Y.; Li, S.; Zhu, Y.; Miao, J.; Xiong, S.; Fei, S.; et al. Aberrant DNA Methylation of SEPT9 and SDC2 in Stool Specimens as an Integrated Biomarker for Colorectal Cancer Early Detection. Front. Genet. 2020, 11, 643. [CrossRef]
Zhang, G.; He, F.; Zhao, G.; Huang, Z.; Li, X.; Xia, X.; Guo, Y.; Xu, W.; Xiong, S.; Ma, Y.; et al. Combining Serum DNA Methylation Biomarkers and Protein Tumor Markers Improved Clinical Sensitivity for Early Detection of Colorectal Cancer. Int. J. Genom. 2021, 2021, 6613987. [CrossRef]
Chen, Z.; Zhao, G.; Wang, K.; Wang, X.; Ma, Y.; Xiong, S.; Zheng, M.; Fei, S. Blood leukocytes methylation levels analysis indicate methylated plasma test is a promising tool for colorectal cancer early detection. J. Cancer 2021, 12, 3678–3685. [CrossRef]
Oh, T.; Kim, N.; Moon, Y.; Kim, M.S.; Hoehn, B.D.; Park, C.H.; Kim, T.S.; Kim, N.K.; Chung, H.C.; An, S. Genome-wide identification and validation of a novel methylation biomarker, SDC2, for blood-based detection of colorectal cancer. J. Mol. Diagn. 2013, 15, 498–507. [CrossRef] [PubMed]
Sun, J.; Zheng, M.Y.; Li, Y.W.; Zhang, S.W. Structure and function of Septin 9 and its role in human malignant tumors. World J. Gastrointest. Oncol. 2020, 12, 619–631. [CrossRef]
Shen, N.; Wang, T.; Li, D.; Zhu, Y.; Xie, H.; Lu, Y. Hypermethylation of the SEPT9 Gene Suggests Significantly Poor Prognosis in Cancer Patients: A Systematic Review and Meta-Analysis. Front. Genet. 2019, 10, 887. [CrossRef] [PubMed]
Kokabu, S.; Rosen, V. BMP3 expression by osteoblast lineage cells is regulated by canonical Wnt signaling. FEBS Open Bio 2018, 8, 168–176. [CrossRef]
Wen, J.; Liu, X.; Qi, Y.; Niu, F.; Niu, Z.; Geng, W.; Zou, Z.; Huang, R.; Wang, J.; Zou, H. BMP3 suppresses colon tumorigenesis via ActRIIB/SMAD2-dependent and TAK1/JNK signaling pathways. J. Exp. Clin. Cancer Res. 2019, 38, 428. [CrossRef] [PubMed]
Vaes, N.; Lentjes, M.H.F.M.; Gijbels, M.J.; Rademakers, G.; Daenen, K.L.; Boesmans, W.; Wouters, K.A.D.; Geuzens, A.; Qu, X.; Steinbusch, H.P.J.; et al. NDRG4, an early detection marker for colorectal cancer, is specifically expressed in enteric neurons. Neurogastroenterol. Motil. 2017, 29, e13095. [CrossRef] [PubMed]
Vaes, N.; Schonkeren, S.L.; Rademakers, G.; Holland, A.M.; Koch, A.; Gijbels, M.J.; Keulers, T.G.; de Wit, M.; Moonen, L.; van der Meer, J.R.M.; et al. Loss of enteric neuronal Ndrg4 promotes colorectal cancer via increased release of Nid1 and Fbln2. EMBO Rep. 2021, 22, e51913. [CrossRef]
Godlewski, J.; Kmiec, Z. Colorectal Cancer Invasion and Atrophy of the Enteric Nervous System: Potential Feedback and Impact on Cancer Progression. Int. J. Mol. Sci. 2020, 21, 3391. [CrossRef]
Bosch, L.J.W.; Melotte, V.; Mongera, S.; Daenen, K.L.J.; Coupe, V.M.H.; van Turenhout, S.T.; Stoop, E.M.; de Wijkerslooth, T.R.; Mulder, C.J.J.; Rausch, C.; et al. Multitarget Stool DNA Test Performance in an Average-Risk Colorectal Cancer Screening Population. Am. J. Gastroenterol. 2019, 114, 1909–1918. [CrossRef]
Mo, S.; Wang, H.; Han, L.; Xiang, W.; Dai, W.; Zhao, P.; Pei, F.; Su, Z.; Ma, C.; Li, Q.; et al. Fecal Multidimensional Assay for Non-Invasive Detection of Colorectal Cancer: Fecal Immunochemical Test, Stool DNA Mutation, Methylation, and Intestinal Bacteria Analysis. Front. Oncol. 2021, 11, 643136. [CrossRef] [PubMed]
Yang, C.; Wu, W.; Yang, Y.; Yang, X.; Sun, J.; Zhang, W.; Liu, K.; Ying, H.; Jiang, S.; Yu, X.; et al. Multitarget stool DNA test compared with fecal occult blood test for colorectal cancer screening. Oncol. Lett. 2020, 20, 1193–1200. [CrossRef] [PubMed]
Zhang, W.; Yang, C.; Wang, S.; Xiang, Z.; Dou, R.; Lin, Z.; Zheng, J.; Xiong, B. SDC2 and TFPI2 Methylation in Stool Samples as an Integrated Biomarker for Early Detection of Colorectal Cancer. Cancer Manag. Res. 2021, 13, 3601–3617. [CrossRef] [PubMed]
Bartak, B.K.; Kalmar, A.; Peterfia, B.; Patai, A.V.; Galamb, O.; Valcz, G.; Spisak, S.; Wichmann, B.; Nagy, Z.B.; Toth, K.; et al. Colorectal adenoma and cancer detection based on altered methylation pattern of SFRP1, SFRP2, SDC2, and PRIMA1 in plasma samples. Epigenetics 2017, 12, 751–763. [CrossRef] [PubMed]
Zhao, G.; Liu, X.; Liu, Y.; Ma, Y.; Yang, J.; Li, H.; Xiong, S.; Fei, S.; Zheng, M.; Zhao, X. Methylated SFRP2 and SDC2 in stool specimens for Colorectal Cancer early detection: A cost-effective strategy for Chinese population. J. Cancer 2021, 12, 2665–2672. [CrossRef] [PubMed]
Freitas, M.; Ferreira, F.; Carvalho, S.; Silva, F.; Lopes, P.; Antunes, L.; Salta, S.; Diniz, F.; Santos, L.L.; Videira, J.F.; et al. A novel DNA methylation panel accurately detects colorectal cancer independently of molecular pathway. J. Transl. Med. 2018, 16, 45. [CrossRef]
Rasmussen, S.L.; Krarup, H.B.; Sunesen, K.G.; Johansen, M.B.; Stender, M.T.; Pedersen, I.S.; Madsen, P.H.; Thorlacius-Ussing, O. Hypemethylated DNA, a circulating biomarker for colorectal cancer detection. PLoS ONE 2017, 12, e0180809. [CrossRef]
Li, J.; Zhou, X.; Liu, X.; Ren, J.; Wang, J.; Wang, W.; Zheng, Y.; Shi, X.; Sun, T.; Li, Z.; et al. Detection of Colorectal Cancer in Circulating Cell-Free DNA by Methylated CpG Tandem Amplification and Sequencing. Clin. Chem. 2019, 65, 916–926. [CrossRef]
Chen, J.; Sun, H.; Tang, W.; Zhou, L.; Xie, X.; Qu, Z.; Chen, M.; Wang, S.; Yang, T.; Dai, Y.; et al. DNA methylation biomarkers in stool for early screening of colorectal cancer. J. Cancer 2019, 10, 5264–5271. [CrossRef]
Wang, D.Y.; He, K.X.; Huang, Y.; Lou, Q.Q.; He, T.; Xu, X. A New Method for the Detection of Colorectal Cancer and the Precancerous Lesions: Occult Blood Testing Combination with Promoter Methylation in the Fecal Sample. J. Cancer 2021, 12, 335–342. [CrossRef] [PubMed]
Cao, Y.; Zhao, G.; Cao, Y.; Chen, Z.; Liu, X.; Yuan, M.; Yang, J.; Wang, X.; Ma, Y.; Liu, Z.; et al. Feasibility of Methylated CLIP4 in Stool for Early Detection of Colorectal Cancer: A Training Study in Chinese Population. Front. Oncol. 2021, 11, 647066. [CrossRef]
Suehiro, Y.; Hashimoto, S.; Goto, A.; Yamaoka, Y.; Yamamoto, N.; Suzuki, N.; Higaki, S.; Fujii, I.; Suzuki, C.; Matsumoto, T.; et al. Fecal DNA Testing of TWIST1 Methylation Identifies Patients With Advanced Colorectal Adenoma Missed by Fecal Immunochemical Test for Hemoglobin. Clin. Transl. Gastroenterol. 2020, 11, e00176. [CrossRef] [PubMed]
Suehiro, Y.; Zhang, Y.; Hashimoto, S.; Takami, T.; Higaki, S.; Shindo, Y.; Suzuki, N.; Hazama, S.; Oka, M.; Nagano, H.; et al. Highly sensitive faecal DNA testing of TWIST1 methylation in combination with faecal immunochemical test for haemoglobin is a promising marker for detection of colorectal neoplasia. Ann. Clin. Biochem. 2018, 55, 59–68. [CrossRef] [PubMed]
Nagai, Y.; Sunami, E.; Yamamoto, Y.; Hata, K.; Okada, S.; Murono, K.; Yasuda, K.; Otani, K.; Nishikawa, T.; Tanaka, T.; et al. LINE-1 hypomethylation status of circulating cell-free DNA in plasma as a biomarker for colorectal cancer. Oncotarget 2017, 8, 11906–11916. [CrossRef] [PubMed]
Shademan, M.; Zare, K.; Zahedi, M.; Mozaffari, H.M.; Hosseini, H.B.; Ghaffarzadegan, K.; Goshayeshi, L.; Dehghani, H. Promoter methylation, transcription, and retrotransposition of LINE-1 in colorectal adenomas and adenocarcinomas. Cancer Cell Int. 2020, 20, 426. [CrossRef] [PubMed]
Jensen, S.Ø.; Øgaard, N.; Ørntoft, M.-B.W.; Rasmussen, M.H.; Bramsen, J.B.; Kristensen, H.; Mouritzen, P.; Madsen, M.R.; Madsen, A.H.; Sunesen, K.G.; et al. Novel DNA methylation biomarkers show high sensitivity and specificity for blood-based detection of colorectal cancer—A clinical biomarker discovery and validation study. Clin. Epigenet. 2019, 11, 158. [CrossRef]
Zhang, Y.; Wu, Q.; Xu, L.; Wang, H.; Liu, X.; Li, S.; Hu, T.; Liu, Y.; Peng, Q.; Chen, Z.; et al. Sensitive detection of colorectal cancer in peripheral blood by a novel methylation assay. Clin. Epigenet. 2021, 13, 90. [CrossRef]
Cao, Y.; Zhao, G.; Yuan, M.; Liu, X.; Ma, Y.; Cao, Y.; Miao, B.; Zhao, S.; Li, D.; Xiong, S.; et al. KCNQ5 and C9orf50 Methylation in Stool DNA for Early Detection of Colorectal Cancer. Front. Oncol. 2021, 10, 621295. [CrossRef]
Mousavi Ardehaie, R.; Hashemzadeh, S.; Behrouz Sharif, S.; Ghojazadeh, M.; Teimoori-Toolabi, L.; Sakhinia, E. Aberrant methylated EDNRB can act as a potential diagnostic biomarker in sporadic colorectal cancer while KISS1 is controversial. Bioengineered 2017, 8, 555–564. [CrossRef]
Kottorou, A.E.; Antonacopoulou, A.G.; Dimitrakopoulos, F.-I.D.; Diamantopoulou, G.; Sirinian, C.; Kalofonou, M.; Theodor-akopoulos, T.; Oikonomou, C.; Katsakoulis, E.C.; Koutras, A.; et al. Deregulation of methylation of transcribed-ultra conserved regions in colorectal cancer and their value for detection of adenomas and adenocarcinomas. Oncotarget 2018, 9, 21411–21428. [CrossRef]
Vedeld, H.M.; Nesbakken, A.; Lothe, R.A.; Lind, G.E. Re-assessing ZNF331 as a DNA methylation biomarker for colorectal cancer. Clin. Epigenet. 2018, 10, 70. [CrossRef]
Li, H.; Wang, Z.; Zhao, G.; Ma, Y.; Chen, Y.; Xue, Q.; Zheng, M.; Fei, S. Performance of a MethyLight assay for methylated SFRP2 DNA detection in colorectal cancer tissue and serum. Int. J. Biol. Markers 2019, 34, 54–59. [CrossRef] [PubMed]
Fan, J.; Li, J.; Guo, S.; Tao, C.; Zhang, H.; Wang, W.; Zhang, Y.; Zhang, D.; Ding, S.; Zeng, C. Genome-wide DNA methylation profiles of low-and high-grade adenoma reveals potential biomarkers for early detection of colorectal carcinoma. Clin. Epigenet. 2020, 12, 56. [CrossRef]
Wu, X.; Zhang, Y.; Hu, T.; He, X.; Zou, Y.; Deng, Q.; Ke, J.; Lian, L.; He, X.; Zhao, D.; et al. A novel cell-free DNA methylation-based model improves the early detection of colorectal cancer. Mol. Oncol. 2021. [CrossRef] [PubMed]
Sui, J.; Wu, X.; Wang, C.; Wang, G.; Li, C.; Zhao, J.; Zhang, Y.; Xiang, J.; Xu, Y.; Nian, W.; et al. Discovery and validation of methylation signatures in blood-based circulating tumor cell-free DNA in early detection of colorectal carcinoma: A case-control study. Clin. Epigenet. 2021, 13, 26. [CrossRef]
Xiao, Z.; Wu, W.; Wu, C.; Li, M.; Sun, F.; Zheng, L.; Liu, G.; Li, X.; Yun, Z.; Tang, J.; et al. 5-Hydroxymethylcytosine signature in circulating cell-free DNA as a potential diagnostic factor for early-stage colorectal cancer and precancerous adenoma. Mol. Oncol. 2021, 15, 138–150. [CrossRef]
Rademakers, G.; Massen, M.; Koch, A.; Draht, M.X.; Buekers, N.; Wouters, K.A.D.; Vaes, N.; De Meyer, T.; Carvalho, B.; Meijer, G.A.; et al. Identification of DNA methylation markers for early detection of CRC indicates a role for nervous system-related genes in CRC. Clin. Epigenet. 2021, 13, 80. [CrossRef] [PubMed]
Vega-Benedetti, A.F.; Loi, E.; Moi, L.; Orru, S.; Ziranu, P.; Pretta, A.; Lai, E.; Puzzoni, M.; Ciccone, L.; Casadei-Gardini, A.; et al. Colorectal Cancer Early Detection in Stool Samples Tracing CpG Islands Methylation Alterations Affecting Gene Expression. Int. J. Mol. Sci. 2020, 21, 4494. [CrossRef] [PubMed]
Jaberie, H.; Hosseini, S.V.; Naghibalhossaini, F. Evaluation of Alpha 1-Antitrypsin for the Early Diagnosis of Colorectal Cancer. Pathol. Oncol. Res. 2020, 26, 1165–1173. [CrossRef]
Liu, J.; Ding, Z.; Li, G.; Tang, L.; Xu, Y.; Luo, H.; Yi, J.; Lu, Y.; Mao, R.; Nan, Q.; et al. Identification and validation of colorectal neoplasia-specific methylation biomarkers based on CTCF-binding sites. Oncotarget 2017, 8, 114183–114194. [CrossRef] [PubMed]
Liu, Y.; Wei, E.; Zhao, J.; Kong, D.; Li, B. Downregulation of SM22α protein by hypermethylation of its promoter in colorectal cancer. Oncol. Lett. 2018, 15, 7675–7680. [CrossRef] [PubMed]
Chang, S.C.; Liew, P.L.; Ansar, M.; Lin, S.Y.; Wang, S.C.; Hung, C.S.; Chen, J.Y.; Jain, S.; Lin, R.K. Hypermethylation and decreased expression of TMEM240 are potential early-onset biomarkers for colorectal cancer detection, poor prognosis, and early recurrence prediction. Clin. Epigenet. 2020, 12, 67. [CrossRef] [PubMed]
Bailey, C.S.; Moldenhauer, H.J.; Park, S.M.; Keros, S.; Meredith, A.L. KCNMA1-linked channelopathy. J. Gen. Physiol. 2019, 151, 1173–1189. [CrossRef]
Basile, M.S.; Fagone, P.; Mangano, K.; Mammana, S.; Magro, G.; Salvatorelli, L.; Li Destri, G.; La Greca, G.; Nicoletti, F.; Puleo, S.; et al. KCNMA1 Expression is Downregulated in Colorectal Cancer via Epigenetic Mechanisms. Cancers 2019, 11, 245. [CrossRef]
Ponomaryova, A.A.; Rykova, E.Y.; Azhikina, T.L.; Bondar, A.A.; Cheremisina, O.V.; Rodionov, E.O.; Boyarko, V.V.; Laktionov, P.P.; Cherdyntseva, N.V. Long interspersed nuclear element-1 methylation status in the circulating DNA from blood of patients with malignant and chronic inflammatory lung diseases. Eur. J. Cancer Prev. 2021, 30, 127–131. [CrossRef]
Xia, T.; Sun, H.; Huang, H.; Bi, H.; Pu, R.; Zhang, L.; Zhang, Y.; Liu, Y.; Xu, J.; Onwuka, J.U.; et al. Androgen receptor gene methylation related to colorectal cancer risk. Endocr. Connect. 2019, 8, 979–987. [CrossRef]
Ashktorab, H.; Rahi, H.; Nouraie, M.; Shokrani, B.; Lee, E.; Haydari, T.; Laiyemo, A.O.; Siegel, P.; Brim, H. GPNMB methylation: A new marker of potentially carcinogenic colon lesions. BMC Cancer 2018, 18, 1068. [CrossRef]
Li, D.; Bai, Y.; Feng, Z.; Li, W.; Yang, C.; Guo, Y.; Lin, C.; Zhang, Y.; He, Q.; Hu, G.; et al. Study of Promoter Methylation Patterns of HOXA2, HOXA5, and HOXA6 and Its Clinicopathological Characteristics in Colorectal Cancer. Front. Oncol. 2019, 9, 394. [CrossRef]
Fadda, A.; Gentilini, D.; Moi, L.; Barault, L.; Leoni, V.P.; Sulas, P.; Zorcolo, L.; Restivo, A.; Cabras, F.; Fortunato, F.; et al. Colorectal cancer early methylation alterations affect the crosstalk between cell and surrounding environment, tracing a biomarker signature specific for this tumor. Int. J. Cancer 2018, 143, 907–920. [CrossRef]
Kerachian, M.A.; Javadmanesh, A.; Azghandi, M.; Shariatpanahi, A.M.; Yassi, M.; Shams Davodly, E.; Talebi, A.; Khadangi, F.; Soltani, G.; Hayatbakhsh, A.; et al. Crosstalk between DNA methylation and gene expression in colorectal cancer, a potential plasma biomarker for tracing this tumor. Sci. Rep. 2020, 10, 2813. [CrossRef]
Heiss, J.A.; Brenner, H. Epigenome-wide discovery and evaluation of leukocyte DNA methylation markers for the detection of colorectal cancer in a screening setting. Clin. Epigenet. 2017, 9, 24. [CrossRef]
Wang, X.; Wang, D.; Zhang, H.; Feng, M.; Wu, X. Genome-wide analysis of DNA methylation identifies two CpG sites for the early screening of colorectal cancer. Epigenomics 2020, 12, 37–52. [CrossRef]
Uhan, S.; Zidar, N.; Tomažič, A.; Hauptman, N. Hypermethylated promoters of genes UNC5D and KCNA1 as potential novel diagnostic biomarkers in colorectal cancer. Epigenomics 2020, 12, 1677–1688. [CrossRef] [PubMed]
Li, D.J.; Feng, Z.C.; Li, X.R.; Hu, G. Involvement of methylation-associated silencing of formin 2 in colorectal carcinogenesis. World J. Gastroenterol. 2018, 24, 5013–5024. [CrossRef] [PubMed]
Zhou, D.; Tang, W.; Zhang, Y.; An, H.X. JAM3 functions as a novel tumor suppressor and is inactivated by DNA methylation in colorectal cancer. Cancer Manag. Res. 2019, 11, 2457–2470. [CrossRef] [PubMed]
Ibrahim, J.; Op de Beeck, K.; Fransen, E.; Croes, L.; Beyens, M.; Suls, A.; Vanden Berghe, W.; Peeters, M.; Van Camp, G. Methylation analysis of Gasdermin E shows great promise as a biomarker for colorectal cancer. Cancer Med. 2019, 8, 2133–2145. [CrossRef] [PubMed]
Panagopoulou, M.; Cheretaki, A.; Karaglani, M.; Balgkouranidou, I.; Biziota, E.; Amarantidis, K.; Xenidis, N.; Kakolyris, S.; Baritaki, S.; Chatzaki, E. Methylation Status of Corticotropin-Releasing Factor (CRF) Receptor Genes in Colorectal Cancer. J. Clin. Med. 2021, 10, 2680. [CrossRef]
Ansar, M.; Wang, C.J.; Wang, Y.H.; Shen, T.H.; Hung, C.S.; Chang, S.C.; Lin, R.K. SMAD3 Hypomethylation as a Biomarker for Early Prediction of Colorectal Cancer. Int. J. Mol. Sci. 2020, 21, 7395. [CrossRef] [PubMed]
Li, D.; Zhang, L.; Fu, J.; Huang, H.; Sun, S.; Zhang, D.; Zhao, L.; Ucheojor Onwuka, J.; Zhao, Y.; Cui, B. SCTR hypermethylation is a diagnostic biomarker in colorectal cancer. Cancer Sci. 2020, 111, 4558–4566. [CrossRef]
Zhang, T.; Cui, G.; Yao, Y.L.; Wang, Q.C.; Gu, H.G.; Li, X.N.; Zhang, H.; Feng, W.M.; Shi, Q.L.; Cui, W. Value of CNRIP1 promoter methylation in colorectal cancer screening and prognosis assessment and its influence on the activity of cancer cells. Arch. Med. Sci. 2017, 13, 1281–1294. [CrossRef]
Otero-Estevez, O.; Gallardo-Gomez, M.; Cadena, M.P.; Rodriguez-Berrocal, F.J.; Cubiella, J.; Ramirez, V.H.; Garcia-Nimo, L.; Chiara, L. Value of Serum NEUROG1 Methylation for the Detection of Advanced Adenomas and Colorectal Cancer. Diagnostics 2020, 10, 437. [CrossRef]
Ye, X.; Mo, M.; Xu, S.; Yang, Q.; Wu, M.; Zhang, J.; Chen, B.; Li, J.; Zhong, Y.; Huang, Q.; et al. The hypermethylation of p16 gene exon 1 and exon 2: Potential biomarkers for colorectal cancer and are associated with cancer pathological staging. BMC Cancer 2018, 18, 1023. [CrossRef] [PubMed]
De’angelis, G.L.; Bottarelli, L.; Azzoni, C.; De’angelis, N.; Leandro, G.; Di Mario, F.; Gaiani, F.; Negri, F. Microsatellite instability in colorectal cancer. Acta Biomed. 2018, 89, 97–101. [CrossRef]
Malki, A.; Elruz, R.A.; Gupta, I.; Allouch, A.; Vranic, S.; Al Moustafa, A.E. Molecular mechanisms of colon cancer progression and metastasis: Recent insights and advancements. Int. J. Mol. Sci. 2021, 22, 130. [CrossRef] [PubMed]
Morán, A. Differential colorectal carcinogenesis: Molecular basis and clinical relevance. World J. Gastrointest. Oncol. 2010, 2, 151. [CrossRef] [PubMed]
Keller, L.; Belloum, Y.; Wikman, H.; Pantel, K. Clinical relevance of blood-based ctDNA analysis: Mutation detection and beyond. Br. J. Cancer 2021, 124, 345–358. [CrossRef]
Song, L.; Li, Y.; Jia, J.; Zhou, G.; Wang, J.; Kang, Q.; Jin, P.; Sheng, J.; Cai, G.; Cai, S.; et al. Algorithm Optimization in Methylation Detection with Multiple RT-qPCR. PLoS ONE 2016, 11, e0163333. [CrossRef]
